Table 1 Patient characteristics according to putative invasive pulmonary aspergillosis diagnosis
All patients (n = 150) | PIPA (n = 50) | No PIPA (n = 100) | p Valuea | ||||
|---|---|---|---|---|---|---|---|
Number (%) | NA (n) | Number (%) | NA (n) | Number (%) | NA (n) | ||
Demographics | |||||||
Male sex, n (%) | 111 (74) | 38 (76) | 73 (73) | 0.52 | |||
Age, yr (IQR) | 66 (60–73) | 67 (60–74) | 66 (70–73) | 0.69 | |||
Weight, kg (IQR) | 77 (65–94) | 19 | 72 (62–87) | 7 | 78 (67–100) | 12 | 0.098 |
Underlying conditions, n (%) | |||||||
Diabetes mellitus | 34 (22.7) | 8 (16) | 26 (26) | 0.21 | |||
Chronic heart failure | 25 (16.7) | 11 (22) | 14 (14) | 0.61 | |||
Chronic renal failure | 6 (4) | 2 (4) | 4 (4) | 1 | |||
Chronic liver failure | 8 (5.3) | 4 (8) | 4 (4) | 0.31 | |||
Solid tumor (CR) | 35 (23.3) | 11 (22) | 24 (24) | 0.74 | |||
Hematological malignancy (CR) | 5 (3.3) | 4 (8) | 1 (1) | 0.57 | |||
Autoimmune disease | 6 (4) | 3 (6) | 3 (3) | 0.39 | |||
Alcohol abuse | 42 (28) | 14 (28) | 28 (28) | 1 | |||
COPD characteristics | |||||||
GOLD grade ≥3, n (% | 78 (62.9) | 26 | 31 (68.9) | 5 | 47 (59.5) | 21 | 0.30 |
FEV1 % (IQR) | 41 (29–59) | 30 | 37 (27–57) | 8 | 43 (30–60) | 22 | 0.47 |
Smoking history, n (%) | 135 (93.7) | 6 | 43 (93.5) | 4 | 92 (93.9) | 2 | 0.92 |
Pack-years (IQR) | 40 (30–60) | 61 | 40 (30–58) | 19 | 45 (30–60) | 42 | 0.66 |
Acute exacerbations,b n (%) | 28 (21.7) | 21 | 8 (17.8) | 5 | 20 (23.8) | 16 | 0.54 |
Corticosteroid use, n (%) | |||||||
Chronic use >3 mo | 22 (14.7) | 13 (26) | 9 (9) | 0.004 | |||
Daily dose >20 mg | 77 (52.7) | 36 (73.5) | 41 (42.3) | <0.001 | |||
Chronic inhalational corticosteroid use | 75 (51) | 3 | 28 (56) | 47 (48.4) | 3 | 0.52 | |
ICU admission | |||||||
Antibiotics (prior 3 months) | 82 (55.4) | 2 | 40 (83.3) | 2 | 42 (42) | <0.001 | |
SAPS II, mean (SD) | 46.9 (13.9) | 46.9 (13.9) | 47 (13.9) | 0.99 | |||
LODS score (IQR) | 6 (4–8) | 6 (3–7) | 6 (4–8) | 0.26 | |||
Supportive therapy in ICU | |||||||
MV duration | 14 (5–27) | 18 (8–26) | 12 (5–26) | 0.60 | |||
Renal replacement therapy, n (%) | 25 (17) | 7 (14) | 18 (18) | 0.57 | |||
Vasopressive or inotropic agents, n (%) | 95 (63) | 32 (64) | 63 (63) | 0.69 | |||
Symptoms, n (%) | |||||||
Refractory fever | 17 (11.3) | 6 (12) | 11 (11) | 0.85 | |||
Recrudescence of fever | 19 (12.7) | 11 (22) | 8 (8) | 0.02 | |||
Pleural effusion | 17 (11.3) | 6 (12) | 11 (11) | 0.85 | |||
Dyspnea | 136 (90.7) | 49 (98) | 87 (87) | 0.07 | |||
Hemoptysis | 8 (5.3) | 5 (10) | 3 (3) | 0.187 | |||
Worsening of respiratory insufficiency | 50 (33.3) | 30 (60) | 20 (20) | <0.001 | |||